Ultragenyx Pharmaceutical (RARE) Cash from Investing Activities (2013 - 2026)

Ultragenyx Pharmaceutical (RARE) has reported Cash from Investing Activities for 14 consecutive years, with -$49.0 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash from Investing Activities fell 140.83% year-over-year to -$49.0 million; the TTM figure through Mar 2026 stood at $67.0 million (up 785.66% YoY), while the FY2025 annual figure was $236.0 million, up 1411.11% from the prior year.
• Cash from Investing Activities rose to -$49.0 million in Q1 2026 per RARE's latest filing, from -$72.2 million in the prior quarter.
• Across five years, Cash from Investing Activities topped out at $120.0 million in Q1 2025 and bottomed at -$275.5 million in Q3 2024.
• Historically, Cash from Investing Activities has averaged $2.7 million across 5 years, with a median of $64.3 million in 2023.
• Annual changes were most pronounced in 2023 — Cash from Investing Activities soared 397.91% — and 2024, when it sank 528.5%.
• Ultragenyx Pharmaceutical's Cash from Investing Activities stood at -$171.6 million in 2022, then surged by 37.64% to -$107.0 million in 2023, then surged by 195.78% to $102.5 million in 2024, then tumbled by 170.48% to -$72.2 million in 2025, then jumped by 32.18% to -$49.0 million in 2026.
• Business Quant data shows RARE's Cash from Investing Activities at -$49.0 million in Q1 2026, -$72.2 million in Q4 2025, and $117.2 million in Q3 2025.